title: Pulmonary metastasectomy as secondary treatment for testicular tumors.
abstract: Patients presenting with synchronous and metachronous metastases of nonseminomatous testicular tumors are candidates for pulmonary metastasectomy after receiving definitive primary treatment, which includes semicastration, eventually retroperitoneal lymphadenectomy, and definitely chemotherapy. One hundred four such patients (age, 14 to 79 years; median age, 27 years) underwent pulmonary metastasectomy from 1972 to 1990, representing 15.8% of the pulmonary metastasectomies performed during the same period. Of the 117 operations performed, eight were repeat operations. Median sternotomy, posterolateral and, later, transverse thoracotomies were the standard surgical approaches used to remove the single and multiple metastases randomly distributed in both lungs. Wedge resections and atypical segmentectomies (66%), lobectomies (15%), anatomic segmentectomies (9%), pneumonectomies (3%), bilobectomies (3%), and mediastinal lymphadenectomies (65.4%) were the various procedures performed. Of the 104 patients, metastasectomy was complete in 80 and incomplete in 24. The 30-day mortality was 2.0%. Life table analysis revealed a survival rate of 77%, 70%, 66%, and 59% at 1, 2, 3, and 5 years, respectively. Of all prognostic factors examined, complete resection of the metastases seems to be the most significant factor influencing the prognosis.
authors.affiliation: Department of Surgery, Chest Hospital, Heidelberg-Rohrbach, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Anyanwu
authors.forename: S
authors.initials: S
authors.lastname: Krysa
authors.forename: H
authors.initials: H
authors.lastname: Buelzebruck
authors.forename: I
authors.initials: I
authors.lastname: Vogt-Moykopf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy